Intratumoral heterogeneity in human solid tumors represents a major barrier for the development of effective molecular treatment strategies, since treatment efficacies will reflect the molecular variegation in individual tumors. In glioblastoma, the generation of composite genomic profiles from bulk tumor samples has allowed one to map the genomic amplifications of putative genetic drivers and to prioritize therapeutic targeting strategies aimed at eradicating the tumor burden. Notably, amplification of multiple receptor tyrosine kinases (RTKs) within a single tumor specimen obtained from patients is frequently observed. In this study, use of a detailed multi-colour FISH mapping procedure in pathological specimens revealed a mutual exclusivity of gene amplification in the majority of glioblastoma tumors examined. In particular, the two most commonly amplified RTK genes, EGFR and PDGFRA, were found to be present in variable proportions across the tumors, with one or the other gene predominating in certain areas of the same specimen. Our findings have profound implications for designing efficacious therapeutic regimens, since it remains unclear how the cells with different gene amplification events contribute to disease propagation or the response to molecular targeted therapies.
Introduction
Cancer heterogeneity presents a major barrier for the development of effective treatment strategies aimed at combating the disease. Intertumoral heterogeneity has long been recognised and catalogued by clinicopathological classification systems, however the imprecision of this approach in accurately predicting an individual patient's outcome has been found to be underpinned by the presence of biologically distinct subtypes identified by molecular profiling (1) within these otherwise similar entities.
Further complicating matters is the appreciation that there also exists considerable heterogeneity within the cells of an individual's tumour mass (2) . Debates as to whether these distinct subpopulations arise through clonal evolution (3) or via propagation of tumour-initiating cells with stem-like qualities (4) are alighting on the idea that the two concepts may be interlinked (5, 6) , and the cellular and genetic context determines which may predominate.
Within glioblastoma, this intratumoral heterogeneity may refer to the concurrent observation of multiple cellular morphologies (7) , differential patterns of vascular proliferation (8) , discrete transcript and/or protein expression patterns (9, 10) , as well as genetic variegation (11, 12) . Despite the long-appreciated 'multiforme' nature of glioblastoma specimens, and a recent in-depth cataloguing of the molecular alterations driving the disease (13, 14) , a thorough mapping of molecular events across individual tumours at a single cell level has been lacking.
DNA copy number profiling has demonstrated that multiple RTK amplifications may frequently be found in the same glioblastoma specimens (13, 14) . Although tumour clonality would imply that these events would be present in all neoplastic cells, we 4 and others have previously noted through detailed fluorescent and chromogenic in situ hybridisation (FISH/CISH) experiments on pathological specimens that not all cells harbour individual amplification events (15, 16 
Materials and Methods

Patient samples
362 formalin-fixed, paraffin-embedded (FFPE) high grade glioma samples were retrieved after Research Ethics Committee approval from 342 consecutive patients diagnosed within the last 5 years from the archives of King's College Hospital, with diagnosis confirmed by re-review (SP, SA-S). The age of the patients was 26-83 years (median 58yrs), and comprised 61%:39% males:females. Clinical follow-up was available for 329 patients, with a median survival of 6.5 months (range 2 days-
5.6yrs).
Fluorescent in situ hybridisation (FISH)
BAC clones were purchased from BACPAC Resources Center (CHORI, CA, USA) and FISH-mapped onto metaphase slides to ensure specificity (EGFR:RP11-433C10/RP11-381G5; centromere 7:RP11-714F8/RP11-714E10/RP11-717E9;
PDGFRA:RP11-58C6/RP11-819D11; centromere 4:RP11-317G22/RP11-191S2).
Probes were labelled with either biotin or DIG using the BioPrime ® DNA Labeling System (Invitrogen, Paisley, UK), hybridised overnight at 37ÛC to FFPE sections, and scanned on the Ariol System (Leica Microsystems, Wetzlar, Germany) at x20 using filters for DAPI/Cy3/FITC.
FISH scoring
On the tissue microarray sections, hybridisation was carried out using differential labelling of one gene and one centromeric probe (EGFR-Cy3/cent7-FITC; PDGFRA- Figure S1) . Any cell ≥5 gene copies was considered amplified. Normal copy number was classed as 1-4 signals per nucleus.
Statistical analysis
All statistical tests were performed in R2.11.0. Correlations between FISH cell counts and categorical variables were performed using ANOVA. Detection of foci showing independent patterns of amplification was carried out by t-test. All tests were twotailed, with a confidence interval of 95%. P values of less than 0.05 were considered statistically significant. 
Results and Discussion
In order to explore the concept of intratumoral genetic heterogeneity more thoroughly, tissue microarrays comprising 342 high grade glioma samples were screened by FISH for cells amplified for genes encoding either EGFR or PDGFRA.
Evidence of high level DNA copy number gain of the gene in as few as a single cell of the TMA core was taken as evidence of amplification. Within assessable cores, we identified 112/294 (38%) cases to harbour EGFR amplification (106/240, 44% glioblastoma; 2/13, 15% anaplastic astrocytoma; 4/41, 10% anaplastic oligodendroglioma) and 49/239 (20%) to harbour PDGFRA amplification (41/191, 21% glioblastoma; 2/11, 18% anaplastic astrocytoma; 6/37, 16% anaplastic oligodendroglioma) ( Table 1) . Whilst the EGFR data were similar to literature reports, the frequency of PDGFRA amplification was approximately twice that from molecular profiling data (13, 14) , and is itself likely an underestimate due to the restricted nature of tumour sampling afforded by using tissue microarrays. Thus it appears that the frequencies of certain abnormalities may be significantly underestimated by focusing only on the composite genetic landscapes afforded by bulk tumour profiling.
A total of 18 cases (8%) contained both gene amplifications. Seventeen of these were glioblastoma, with a single case of anaplastic oligodendroglioma. We utilised two-colour FISH with differential labelling of probes specific to EGFR and PDGFRA on whole sections from these samples, and assessed the relative copy numbers per cell of each gene. We observed a high degree of variability in gene copy number of both genes in individual cells across the entire pathological specimen. Coamplification was observed as either co-segregation of double minutes containing both genes ( Figure 1A ), or in one case, a homogenously staining region (HSR) of EGFR amplification alongside PDGFRA double minutes ( Figure 1B ). To our surprise, however, we also discovered a high degree of mutual exclusivity of gene Author Manuscript Published OnlineFirst on February 6, 2012; DOI: 10.1158/0008-5472. reported between PDGFRA abnormalities and an oligodendroglial phenotype (18) , though in these tumours, EGFR amplifications are not concurrently present.
These data are remarkably consistent with, and complimentary to, a recent study describing the same phenomenon in glioblastoma as "mosaic amplification" (19) .
Taken together, these studies are suggestive of distinct subpopulations of glioblastoma cells marked by differential gene amplification, and these authors noted in particular that each subpopulation was derived form a single precursor, was actively dividing, with the specific amplification driving protein expression (19) . The relative contributions of cell populations harbouring one or other gene amplification to disease progression, and the implications for novel treatment strategies, remains to be elucidated. (A) Frequency of amplifications observed by FISH in an initial tissue microarray screen of 342 high grade glioma patients. Tumours are taken as a whole, as well as subdivided by histology, and the log-rank test applied to determine univariate prognostic significance (*p<0.05).
